newsfilter
← Latest News
GlobeNewswire·

ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

  • Ascentage Pharma presented updated data on Olverembatinib at the 67th ASH Annual Meeting in Orlando for second-line treatment of chronic-phase chronic myeloid leukemia (CML-CP).
  • Patients who failed first-line second-generation TKI therapy achieved a 76.7% complete cytogenetic response (CCyR) rate.
  • Major molecular response (MMR) reached 60% at 21 treatment cycles, indicating deepening responses with extended duration.
  • In all patients resistant or intolerant to one prior TKI line without the T315I mutation, CCyR was 71.8% and MMR was 43.6%.
  • Safety profile remained consistent with prior reports, showing no new safety signals.
  • Treatment-related adverse events occurred in 89.4% of patients, including 44.7% experiencing grade ≥3 events, with no deaths reported.
  • Olverembatinib is the first third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations or resistance to first- and second-generation TKIs.
  • All approved indications for Olverembatinib in China are covered by the National Reimbursement Drug List (NRDL).
  • Ascentage Pharma is conducting global Phase III trials for Olverembatinib in CML-CP, Philadelphia chromosome-positive acute lymphoblastic leukemia, and SDH-deficient gastrointestinal stromal tumors.
  • An exclusive option agreement exists with Takeda for potential global rights to develop and commercialize Olverembatinib outside mainland China, Hong Kong, Macau, and Taiwan.